Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification
Abstract Background Interphase fluorescence in situ hybridization (FISH) of bone marrow cells has been confirmed to be a direct and valid method to assess the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) amplification in patients with bone marrow metastatic neurob...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-11-01
|
| Series: | Cancer Communications |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40880-019-0409-1 |
| _version_ | 1818825781504114688 |
|---|---|
| author | Zhi-Xia Yue Tian-Yu Xing Chao Gao Shu-Guang Liu Wen Zhao Qian Zhao Xi-Si Wang Mei Jin Xiao-Li Ma |
| author_facet | Zhi-Xia Yue Tian-Yu Xing Chao Gao Shu-Guang Liu Wen Zhao Qian Zhao Xi-Si Wang Mei Jin Xiao-Li Ma |
| author_sort | Zhi-Xia Yue |
| collection | DOAJ |
| description | Abstract Background Interphase fluorescence in situ hybridization (FISH) of bone marrow cells has been confirmed to be a direct and valid method to assess the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) amplification in patients with bone marrow metastatic neuroblastoma. MYCN amplification alone, however, is insufficient for pretreatment risk stratification. Chromosome band 11q23 deletion has recently been included in the risk stratification of neuroblastoma. In the present study, we aimed to evaluate the biological characteristics and prognostic impact of 11q23 deletion and MYCN amplification in patients with bone marrow metastatic neuroblastoma. Methods We analyzed the MYCN and 11q23 statuses of 101 patients with bone marrow metastatic neuroblastoma using interphase FISH of bone marrow cells. We specifically compared the biological characteristics and prognostic impact of both aberrations. Results MYCN amplification and 11q23 deletion were seen in 12 (11.9%) and 40 (39.6%) patients. The two markers were mutually exclusive. MYCN amplification occurred mainly in patients with high lactate dehydrogenase (LDH) and high neuron-specific enolase (NSE) levels (both P < 0.001), and MYCN-amplified patients had more events (tumor relapse, progression, or death) than MYCN-normal patients (P = 0.004). 11q23 deletion was associated only with age (P = 0.001). Patients with MYCN amplification had poorer outcomes than those with normal MYCN (3-year event-free survival [EFS] rate: 8.3 ± 8.0% vs. 43.8 ± 8.5%, P < 0.001; 3-year overall survival [OS] rate: 10.4 ± 9.7% vs. 63.5% ± 5.7%, P < 0.001). 11q23 deletion reflected a poor prognosis only for patients with normal MYCN (3-year EFS rate: 34.3 ± 9.5% vs. 53.4 ± 10.3%, P = 0.037; 3-year OS rate: 42.9 ± 10.4% vs. 75.9 ± 6.1%, P = 0.048). Those with both MYCN amplification and 11q23 deletion had the worst outcome (P < 0.001). Conclusions Chromosome band 11q23 deletion predicts poor prognosis only in bone marrow metastatic neuroblastoma patients without MYCN amplification. Combined assessment of the two markers was much superior to single-marker assessment in recognizing the patients at a high risk of disease progression. |
| first_indexed | 2024-12-19T00:17:13Z |
| format | Article |
| id | doaj.art-db7c94a0b6d4487db9981d283101fb51 |
| institution | Directory Open Access Journal |
| issn | 2523-3548 |
| language | English |
| last_indexed | 2024-12-19T00:17:13Z |
| publishDate | 2019-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Communications |
| spelling | doaj.art-db7c94a0b6d4487db9981d283101fb512022-12-21T20:45:45ZengWileyCancer Communications2523-35482019-11-013911910.1186/s40880-019-0409-1Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplificationZhi-Xia Yue0Tian-Yu Xing1Chao Gao2Shu-Guang Liu3Wen Zhao4Qian Zhao5Xi-Si Wang6Mei Jin7Xiao-Li Ma8Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in Children Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthBeijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in Children Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthBeijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in Children Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthBeijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in Children Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthBeijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in Children Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthBeijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in Children Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthBeijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in Children Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthBeijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in Children Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthBeijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in Children Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthAbstract Background Interphase fluorescence in situ hybridization (FISH) of bone marrow cells has been confirmed to be a direct and valid method to assess the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) amplification in patients with bone marrow metastatic neuroblastoma. MYCN amplification alone, however, is insufficient for pretreatment risk stratification. Chromosome band 11q23 deletion has recently been included in the risk stratification of neuroblastoma. In the present study, we aimed to evaluate the biological characteristics and prognostic impact of 11q23 deletion and MYCN amplification in patients with bone marrow metastatic neuroblastoma. Methods We analyzed the MYCN and 11q23 statuses of 101 patients with bone marrow metastatic neuroblastoma using interphase FISH of bone marrow cells. We specifically compared the biological characteristics and prognostic impact of both aberrations. Results MYCN amplification and 11q23 deletion were seen in 12 (11.9%) and 40 (39.6%) patients. The two markers were mutually exclusive. MYCN amplification occurred mainly in patients with high lactate dehydrogenase (LDH) and high neuron-specific enolase (NSE) levels (both P < 0.001), and MYCN-amplified patients had more events (tumor relapse, progression, or death) than MYCN-normal patients (P = 0.004). 11q23 deletion was associated only with age (P = 0.001). Patients with MYCN amplification had poorer outcomes than those with normal MYCN (3-year event-free survival [EFS] rate: 8.3 ± 8.0% vs. 43.8 ± 8.5%, P < 0.001; 3-year overall survival [OS] rate: 10.4 ± 9.7% vs. 63.5% ± 5.7%, P < 0.001). 11q23 deletion reflected a poor prognosis only for patients with normal MYCN (3-year EFS rate: 34.3 ± 9.5% vs. 53.4 ± 10.3%, P = 0.037; 3-year OS rate: 42.9 ± 10.4% vs. 75.9 ± 6.1%, P = 0.048). Those with both MYCN amplification and 11q23 deletion had the worst outcome (P < 0.001). Conclusions Chromosome band 11q23 deletion predicts poor prognosis only in bone marrow metastatic neuroblastoma patients without MYCN amplification. Combined assessment of the two markers was much superior to single-marker assessment in recognizing the patients at a high risk of disease progression.http://link.springer.com/article/10.1186/s40880-019-0409-1NeuroblastomaMYCN amplification11q23 deletionFluorescence in situ hybridizationBone marrow metastasisEvent-free survival |
| spellingShingle | Zhi-Xia Yue Tian-Yu Xing Chao Gao Shu-Guang Liu Wen Zhao Qian Zhao Xi-Si Wang Mei Jin Xiao-Li Ma Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification Cancer Communications Neuroblastoma MYCN amplification 11q23 deletion Fluorescence in situ hybridization Bone marrow metastasis Event-free survival |
| title | Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification |
| title_full | Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification |
| title_fullStr | Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification |
| title_full_unstemmed | Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification |
| title_short | Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification |
| title_sort | chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without mycn amplification |
| topic | Neuroblastoma MYCN amplification 11q23 deletion Fluorescence in situ hybridization Bone marrow metastasis Event-free survival |
| url | http://link.springer.com/article/10.1186/s40880-019-0409-1 |
| work_keys_str_mv | AT zhixiayue chromosomeband11q23deletionpredictspoorprognosisinbonemarrowmetastaticneuroblastomapatientswithoutmycnamplification AT tianyuxing chromosomeband11q23deletionpredictspoorprognosisinbonemarrowmetastaticneuroblastomapatientswithoutmycnamplification AT chaogao chromosomeband11q23deletionpredictspoorprognosisinbonemarrowmetastaticneuroblastomapatientswithoutmycnamplification AT shuguangliu chromosomeband11q23deletionpredictspoorprognosisinbonemarrowmetastaticneuroblastomapatientswithoutmycnamplification AT wenzhao chromosomeband11q23deletionpredictspoorprognosisinbonemarrowmetastaticneuroblastomapatientswithoutmycnamplification AT qianzhao chromosomeband11q23deletionpredictspoorprognosisinbonemarrowmetastaticneuroblastomapatientswithoutmycnamplification AT xisiwang chromosomeband11q23deletionpredictspoorprognosisinbonemarrowmetastaticneuroblastomapatientswithoutmycnamplification AT meijin chromosomeband11q23deletionpredictspoorprognosisinbonemarrowmetastaticneuroblastomapatientswithoutmycnamplification AT xiaolima chromosomeband11q23deletionpredictspoorprognosisinbonemarrowmetastaticneuroblastomapatientswithoutmycnamplification |